The activation of AMPK combined with anti-PD-1 and anti-CTLA4 antibodies or with a HMGCR inhibitor exhibited synergic anti-cancer activity in murine tumor models, supporting their potential clinical use. The gene discussed is PRKAA2; the disease is neoplasm.